Down 65% in 4 Weeks, Here’s Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc.  (VRCA)

Down 65% in 4 Weeks, Here’s Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA)

a downtrend has been apparent in Verrica Pharmaceuticals Inc. (VRCA) lately with too much selling pressure. The stock has declined 65% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company’s ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

Guide to Identifying Oversold Stocks

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock’s price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why VRCA Could Bounce Back Before Long

The RSI reading of 27.08 for VRCA is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for VRCA has increased 38.1%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, VRCA currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock’s potential turnaround in the near term. You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>

Free: Top Stocks for the $30 Trillion Metaverse Boom

The metaverse is a quantum leap for the internet as we currently know it – and it will make some investors rich. Just like the internet, the metaverse is expected to transform how we live, work and play. Zacks has put together a new special report to help readers like you target big profits. The Metaverse – What is it? And How to Profit with These 5 Pioneering Stocks reveals specific stocks set to skyrocket as this emerging technology develops and expands.

Download Zacks’ Metaverse Report now >>

Click to get this free report

Verrica Pharmaceuticals Inc. (VRCA): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Comment

Your email address will not be published.